Revelation Biosciences, Inc. (REVB)
NASDAQ: REVB · Real-Time Price · USD
0.759
-0.019 (-2.46%)
At close: Nov 20, 2024, 4:00 PM
0.737
-0.022 (-2.87%)
Pre-market: Nov 21, 2024, 6:33 AM EST
Revelation Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Selling, General & Admin | 4.54 | 4.51 | 5.49 | 5.04 | 1.23 |
| Research & Development | 4 | 4.15 | 5.38 | 6.91 | 2.56 |
| Operating Expenses | 8.55 | 8.66 | 10.86 | 11.95 | 3.8 |
| Operating Income | -8.55 | -8.66 | -10.86 | -11.95 | -3.8 |
| Other Non Operating Income (Expenses) | -6.97 | 8.54 | 0.03 | -0.04 | 0 |
| Pretax Income | -15.52 | -0.12 | -10.83 | -11.99 | -3.8 |
| Net Income | -15.52 | -0.12 | -10.83 | -11.99 | -3.8 |
| Net Income to Common | -15.52 | -0.12 | -10.83 | -11.99 | -3.8 |
| Shares Outstanding (Basic) | 1 | 0 | 0 | - | - |
| Shares Outstanding (Diluted) | 1 | 0 | 0 | - | - |
| Shares Change (YoY) | 525.77% | 215.00% | - | - | - |
| EPS (Basic) | -10.93 | -0.53 | -149.20 | - | - |
| EPS (Diluted) | -10.93 | -0.53 | -149.20 | - | - |
| Free Cash Flow | -16.61 | -7.29 | -11.22 | -11.22 | -2.13 |
| Free Cash Flow Per Share | -11.70 | -31.87 | -154.57 | - | - |
| EBITDA | -8.52 | -8.63 | -10.84 | -11.93 | - |
| D&A For EBITDA | 0.03 | 0.03 | 0.03 | 0.02 | - |
| EBIT | -8.55 | -8.66 | -10.86 | -11.95 | -3.8 |
Source: S&P Capital IQ. Standard template.
Financial Sources.